太原市美人帮美甲加盟电话多少钱长寿区沐一美甲加盟电话多少钱,济南市椿树美甲加盟电话多少钱,天水市美甲加盟店需要多少钱电话多少钱,内江市0元美甲加盟电话多少钱,顺义区维蒂娜美甲加盟电话多少钱,德阳市维蒂娜美甲加盟电话多少钱,南京市智能美甲加盟电话多少钱

WASHINGTON, Oct. 3 (Xinhua) -- Researchers at St. Michael's Hospital in Canada have discovered a new function for an enzyme that may protect against organ injury and death from anemia, according to a study appearing Monday in the U.S. journal of the Proceeding of the National Academy of Sciences.Researchers found that when people have anemia, neuronal nitric oxide synthase (nNOS) -- an enzyme in nerve cells that produces nitric oxide, an important signaling molecule in the body -- increases the body's ability to respond, adapt to low oxygen levels and makes the body more efficient in delivering oxygen to tissues. They also found that levels of nNOS in the brain increased in anemic mice, and that the mice without this enzyme die earlier, and with higher hemoglobin levels."Identifying this mechanism may lead to new therapies and approaches to improving outcomes for anemic patients," said Dr. Greg Hare, a researcher at the Li Ka Shing Knowledge Institute of the hospital and one of the lead investigators of the study.Anemia occurs when blood has a lower than normal number of red blood cells or hemoglobin -- an iron-rich protein that carries oxygen from the lungs and heart to the rest of the body. Cells need oxygen to survive and to produce energy for all bodily functions. The condition has many different causes including infection (malaria, HIV, parasites), nutritional deficiencies (iron, folate, B12), genetic mutations, pregnancy, trauma and surgical blood loss."This research will help us identify when an anemic patient is at greatest risk for injury and death when undergoing surgery," said Hare. "Research is underway to test these findings in humans."

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

BEIJING, Oct. 20 (Xinhuanet) -- British scientists used bacteria and DNA to build basic components for digital devices in a new research, according to media reports, suggesting biological computers come closer to reality.Digital devices are based on logic gates, fundamental building blocks in silicon circuitry, said Professor Richard Kitney, leading researcher of the research published in the journal Nature Communications, "Without them, we could not process digital information."According to Science Daily, Professor Kitney and his colleagues from the Imperial College London replicated the building blocks using bacteria and DNA, forming biological logic gates, which paved the way for building more complex biological processors in the future.The researchers hoped biological computers can be applied to monitoring human health in the future.They believed that small biological processors, inserted in human bodies, could roam inside the bodies, monitor the health, and correct any problems they found.These biological logic gates are the most advanced created by scientists. But there is still a long way to go to apply them in reality, said Professor Kitney.

SHANGHAI, Jan. 11 (Xinhua) -- China has allowed the Bank of East Asia (BEA) to issue yuan-denominated bonds in Hong Kong for a second time, about three years after it became the first foreign-invested bank to make a yuan bond issuance, the bank said Wednesday.BEA China Ltd, a wholly-owned subsidiary of the BEA, was given the approval by the National Development and Reform Commission of China to issue yuan bonds in Hong Kong, it said.Details on the amounts and timing of the offerings weren't available. In 2009, in a major landmark, the BEA issued its first yuan bonds in Hong Kong in an aggregate principal amount of 4 billion yuan (630 million U.S. dollars).The BEA was among the first foreign-invested banks to be given the green light to issue yuan-denominated bonds in Hong Kong, a move analysts say will bolster the international influence of the Chinese currency, also known as renminbi.Sun Minjie, deputy head of BEA China, said the second bond issuance will give the bank stable access to capital, improve its debt portfolio, and support its development on the Chinese mainland.

HEFEI, Nov. 25 (Xinhua) -- China's leading private automaker, Chery Automobile Co., Ltd., is expected to export a record 170,000 units of vehicles in 2011, marking the highest annual export figure in the company's history, a company manager said Friday.Chery exported 135,556 units of vehicles in the first ten months of this year, up 77.3 percent from a year earlier. This total accounts for 35.3 percent of total passenger vehicle exports of domestic brands, said Feng Ping, deputy general manager of Chery International.The central Anhui province-based carmaker started exporting cars in 2001, when it sold ten cars to Syria, and has since led export sales amongst Chinese automakers.The company exports its products to more than 80 countries and regions, and has established 3 research institutions, a service network of 1,000 dealers and more than 800 service stations overseas.